Skip to main content
Fusen Pharmaceutical Company Limited logo

Fusen Pharmaceutical Company Limited — Investor Relations & Filings

Ticker · 1652 ISIN · KYG370981030 HKEX Manufacturing
Open in API
Filings indexed 447 across all filing types
Latest filing 2026-05-11 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1652

About Fusen Pharmaceutical Company Limited

http://www.fusenyy.com

Fusen Pharmaceutical Company Limited operates as a comprehensive pharmaceutical enterprise, integrating the cultivation of Chinese herbal medicine, drug research and development (R&D), production, and sales. The company manufactures and markets a diverse range of pharmaceutical products, including tablets, capsules, and oral solutions. Its therapeutic focus spans critical areas such as respiratory tract conditions, antiviral infections, cardio cerebrovascular diseases, digestion, and metabolism. Fusen is known for providing cold remedies, particularly those based on Shuanghuanglian, and actively develops and markets prescription drugs, demonstrating a commitment to both traditional and modern pharmaceutical solutions.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT "LORNOXICAM FOR INJECTION" APPROVED FOR MARKETING
Regulatory Filings Classification · 80% confidence The document is a voluntary announcement regarding product approval (“Lornoxicam for Injection” approved for marketing) by the board of a Hong Kong–listed company. It does not contain financial results, management discussion, capital transactions, or AGM materials. It is a standalone corporate announcement of a material development that does not fit any specific category, making it a general regulatory announcement. Hence it should be classified under Regulatory Filings (RNS).
2026-05-11 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a monthly return filing for an equity issuer listed on the Hong Kong Stock Exchange, detailing movements in securities, share capital, issued shares, share options, and confirmations related to compliance with listing rules. It is a regulatory submission reporting share capital and shareholding movements for the month ended 30 April 2026. The document does not contain financial statements, earnings data, management discussion, or audit information. It is a regulatory compliance filing specific to share capital and shareholding movements, not a financial report or announcement of voting results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-05-04 English
Notification Letter to Non-Registered Holders and Reply Form - Notice of Publication of Annual Report 2025 and Circular of Annual General Meeting
Report Publication Announcement Classification · 100% confidence The document is a notification letter dated April 30, 2026, from Fusen Pharmaceutical Company Limited to non-registered shareholders. It informs recipients about the publication of the company's Annual Report 2025 and the Circular of the Annual General Meeting (AGM). The letter explains that these documents are available electronically on the HKEX and company websites and provides instructions on how shareholders can request printed copies or electronic delivery of future corporate communications. The document does not contain the actual annual report or AGM circular but serves as a notice of their availability and instructions for access. It is a typical example of a Report Publication Announcement (RPA), as it announces the release of the annual report and AGM circular rather than presenting the reports themselves.
2026-04-30 English
Notification Letter to Registered Shareholders and Reply Form - Notice of Publication of Annual Report 2025, Circular and Proxy Form of Annual General Meeting
Report Publication Announcement Classification · 100% confidence The document is a notification letter dated 30 April 2026 from Fusen Pharmaceutical Company Limited to its registered shareholders. It announces the publication of the Annual Report 2025, Circular, and Proxy Form for the Annual General Meeting. The letter informs shareholders that these documents are available electronically on the HKEX and company websites and provides instructions on how to receive printed copies if needed. It also explains the company's adoption of electronic dissemination of corporate communications pursuant to HKEX Listing Rules. The document does not contain the actual annual report or financial statements but rather serves as a notice of publication and instructions for shareholders to access or request these documents. The length is about 13,519 characters, which is relatively short for a full annual report but typical for a notification letter. According to the MENU VS MEAL rule, this is an announcement of the report's publication, not the report itself. Therefore, the correct classification is Report Publication Announcement (RPA).
2026-04-30 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 100% confidence The document is a notice for the Annual General Meeting (AGM) of Fusen Pharmaceutical Company Limited scheduled for 29 May 2026. It includes details about the meeting agenda such as receiving and adopting the audited financial statements, re-election of directors, re-appointment of auditors, and approval of share issuance and repurchase mandates. The document is a formal meeting notice and does not contain the actual annual report or financial statements themselves. It is not a transcript, earnings release, or any other report type. The presence of the phrase 'NOTICE OF ANNUAL GENERAL MEETING' and the detailed agenda confirms this is an AGM Information document. The document length (13,502 characters) is consistent with a detailed AGM notice rather than a brief announcement or proxy statement. Therefore, the correct classification is AGM Information (AGM-R).
2026-04-30 English
FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING (or at any adjournment thereof)
AGM Information Classification · 95% confidence The document is a Form of Proxy for use at the Annual General Meeting (AGM) of Fusen Pharmaceutical Company Limited. It includes instructions for shareholders to appoint proxies to vote on various resolutions at the AGM, including adoption of audited financial statements, re-election of directors, appointment of auditors, and mandates related to share allotment and repurchase. The content is procedural and related to voting arrangements for the AGM rather than the AGM materials or presentations themselves. Therefore, this document fits the category of AGM Information, which covers presentations and materials shared during the AGM, including proxy forms.
2026-04-30 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.